Network Meta-Analysis of Randomized Trials in Relapsed/Refractory Multiple Myeloma: Relative Efficacy for Patients Who Are Lenalidomide-Refractory

被引:0
|
作者
Kastritis, Efstathios [1 ]
Harvey, Rebecca [2 ]
Cranmer, Holly [3 ]
Bianco, Martina [4 ]
Fenu, Elisabetta [5 ]
La Porte, Charles [6 ]
Ramasamy, Karthik [7 ]
机构
[1] Natl & Kapodistrian Univ Athens, Sch Med, Dept Clin Therapeut, Athens, Greece
[2] Cabourn Stat Ltd, Warrington, England
[3] Cranmer Consultancy Ltd, Sheffield, England
[4] Menarini Ric, Pomezia, Italy
[5] Menarini GmbH, Zurich, Switzerland
[6] Menarini Stemline Therapeut, New York, NY USA
[7] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England
关键词
D O I
10.1182/blood-2023-180947
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页数:3
相关论文
共 50 条
  • [1] Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients
    Botta, Cirino
    Ciliberto, Domenico
    Rossi, Marco
    Staropoli, Nicoletta
    Cuce, Maria
    Galeano, Teresa
    Tagliaferri, Pierosandro
    Tassone, Pierfrancesco
    BLOOD ADVANCES, 2017, 1 (07) : 455 - 466
  • [2] Network meta-analysis of efficacy of ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma
    DerSarkissian, Maral
    Cranmer, Holly
    Dabora, Jonathan
    Bocharova, Iryna
    Cherepanov, Dasha
    Cheng, Mu
    Bhak, Rachel H.
    Duh, Mei Sheng
    HEMATOLOGY, 2023, 28 (01)
  • [3] A Systematic Review and Network Meta-analysis of Randomized Data on Efficacy of Novel Therapy Combinations in Patients with Lenalidomide-refractory Multiple Myeloma
    Mohyuddin, Ghulam Rehman
    Hampton, Jill
    Aziz, Muhammad
    Khuder, Sadik
    Malik, Saad
    McClune, Brian
    Abdallah, Al-Ola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (07): : 489 - 496
  • [4] Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
    Paludo, Jonas
    Mikhael, Joseph R.
    LaPlant, Betsy R.
    Halvorson, Alese E.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis K.
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Go, Ronald S.
    Lin, Yi
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Chanan-Khan, Asher A.
    Ailawadhi, Sikander
    Stewart, A. Keith
    Reeder, Craig B.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    Lacy, Martha Q.
    BLOOD, 2017, 130 (10) : 1198 - 1204
  • [5] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
    Huang, Zeng-Yi
    Jin, Xiao-Qin
    Liang, Qi-Lian
    Zhang, Ding-Yue
    Han, Han
    Wang, Zhen-Wei
    MEDICINE, 2023, 102 (38) : E35319
  • [6] How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
    de Arriba de la Fuente, Felipe
    Montes Gaisan, Carmen
    de la Rubia Comos, Javier
    CANCERS, 2023, 15 (01)
  • [7] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
    Shafei, Laila
    Bashir, Shaima
    Chan, Esther W.
    Abushanab, Dina
    Hamad, Anas
    Al-Badriyeh, Daoud
    CURRENT PROBLEMS IN CANCER, 2024, 50
  • [8] Efficacy and safety of selinexor for patients with relapsed and refractory multiple myeloma: A meta-analysis
    Al-Badriyeh, Daoud
    Shafei, Laila
    Bashir, Shaima
    Abushanab, Dina
    Hamad, Anas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 263 - 263
  • [9] Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
    Xiaohui Gao
    Hui Zeng
    Xiaoyan Zhao
    Haibing Wu
    Minchao Yan
    Yuan Li
    Gang Zhang
    Fei Sun
    BMC Cancer, 23
  • [10] EFFICACY AND SAFETY OF SELINEXOR FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A META-ANALYSIS
    Abushanab, D.
    Mraiche, F.
    Al-Badriyeh, D.
    VALUE IN HEALTH, 2021, 24 : S22 - S22